ATE331796T1 - Rhesus-karzinoembryonales antigen, dieses codierende nukleotide und verwendungen davon - Google Patents

Rhesus-karzinoembryonales antigen, dieses codierende nukleotide und verwendungen davon

Info

Publication number
ATE331796T1
ATE331796T1 AT04709218T AT04709218T ATE331796T1 AT E331796 T1 ATE331796 T1 AT E331796T1 AT 04709218 T AT04709218 T AT 04709218T AT 04709218 T AT04709218 T AT 04709218T AT E331796 T1 ATE331796 T1 AT E331796T1
Authority
AT
Austria
Prior art keywords
cea
rhcea
antigen
development
rhesus
Prior art date
Application number
AT04709218T
Other languages
English (en)
Inventor
L Aurisicchio
Gennaro Ciliberto
Armin Lahm
Monica Nicola La
P Monaci
Fabio Palombo
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Application granted granted Critical
Publication of ATE331796T1 publication Critical patent/ATE331796T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00118Cancer antigens from embryonic or fetal origin
    • A61K39/001182Carcinoembryonic antigen [CEA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007Carcino-embryonic Antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04709218T 2003-02-13 2004-02-09 Rhesus-karzinoembryonales antigen, dieses codierende nukleotide und verwendungen davon ATE331796T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44720303P 2003-02-13 2003-02-13

Publications (1)

Publication Number Publication Date
ATE331796T1 true ATE331796T1 (de) 2006-07-15

Family

ID=32869610

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04709218T ATE331796T1 (de) 2003-02-13 2004-02-09 Rhesus-karzinoembryonales antigen, dieses codierende nukleotide und verwendungen davon

Country Status (9)

Country Link
US (1) US20060228335A1 (de)
EP (1) EP1597370B1 (de)
JP (1) JP2006518202A (de)
AT (1) ATE331796T1 (de)
AU (1) AU2004211481A1 (de)
CA (1) CA2514969A1 (de)
DE (1) DE602004001395T2 (de)
ES (1) ES2267046T3 (de)
WO (1) WO2004072287A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1658370A1 (de) * 2003-08-22 2006-05-24 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Für das karzinoembryonale antigen aus rhesusaffe codierendes synthetisches gen und verwendungen davon
RU2380375C2 (ru) 2004-02-11 2010-01-27 Иституто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа Слитые белки карциноэмбрионального антигена
EP1937851A4 (de) * 2005-10-19 2010-08-25 Ibc Pharmaceuticals Inc Verfahren und zusammensetzungen zum erzeugen bioaktiver gruppen von erhöhter komplexität sowie ihre verwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274087A (en) * 1986-08-13 1993-12-28 Molecular Diagnostics, Inc. cDNA coding for carcinoembryonic antigen (CEA)
AU674492B2 (en) * 1991-05-06 1997-01-02 United States of America, as represented by the Department of Health and Human Services, The Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
JP4540033B2 (ja) * 1999-10-22 2010-09-08 サノフィ パストゥール リミテッド 腫瘍抗原に対する免疫応答を誘発および/または増強する方法
EP1658370A1 (de) * 2003-08-22 2006-05-24 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Für das karzinoembryonale antigen aus rhesusaffe codierendes synthetisches gen und verwendungen davon

Also Published As

Publication number Publication date
CA2514969A1 (en) 2004-08-26
DE602004001395T2 (de) 2007-08-09
EP1597370B1 (de) 2006-06-28
DE602004001395D1 (de) 2006-08-10
WO2004072287A1 (en) 2004-08-26
US20060228335A1 (en) 2006-10-12
JP2006518202A (ja) 2006-08-10
ES2267046T3 (es) 2007-03-01
EP1597370A1 (de) 2005-11-23
AU2004211481A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
EP1716173B8 (de) Fusionsproteine des karzinomembryonalen antigens und deren verwendungen
NO20055708L (no) Syntetisk gen som koder for humant karsinembryonalt antigen og anvendelser derav
NO20060813L (no) Syntetisk gen som koder for human epidermalvekstfaktor 2/NEU og andvendelser derav
IL198012A0 (en) Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
WO2018172533A3 (en) T cell receptors and immune therapy using the same against prame positive cancers
MX2019015742A (es) Receptores de celulas t novedosos, e inmunoterapia usando los mismos.
MX2019011260A (es) Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame.
ZA202100107B (en) Chimeric antigen receptors with bcma specificity and uses thereof
TR200700740T2 (tr) Nogo genlerinin nükleotid ve protein dizileri ve bunlar bazında yöntemler
SG170080A1 (en) Human monoclonal antibodies to o8e
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
MX2009005189A (es) Anticuerpos humanos monoclonales para btla y metodos de uso.
HUP0201737A2 (hu) Anti-CTLA-4 antitestek alkalmazása
MXPA05008794A (es) Antigeno de glicoproteina sima135 expresado en celulas tumorales humanas metastasicas.
DK1536006T3 (da) Cancerantigener og anvendelse deraf
WO2004002408A3 (en) Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase
HUP0101991A2 (hu) Peszticid toxinok és az ezeket kódoló nukleotid szekvenciák
ATE331796T1 (de) Rhesus-karzinoembryonales antigen, dieses codierende nukleotide und verwendungen davon
WO2005053604A3 (en) Antibodies specific for cancer associated antigen sm5-1 and uses thereof
HUP0204216A2 (en) A new use of antibodies as vaccines
WO2003055908A3 (en) Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
Baba et al. Identification of a lung cancer antigen evading CTL attack due to loss of human leukocyte antigen (HLA) class I expression
Hatzi et al. B-cell chronic lymphocytic leukemia (B-CLL) cells express antibodies reactive with antigenic epitopes expressed on the surface of common bacteria.
WO2003084996A3 (en) Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
WO2006120473A3 (en) Mhc class i and ii peptide antigens derived from tumour antigen 5t4

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties